Apogee Therapeutics (NASDAQ: APGE) surged approximately 137% in pre-market trading after announcing a definitive agreement to be acquired by AbbVie (NYSE: ABBV) in an all-cash transaction valued at roughly $10.9 billion. The deal marks one of the largest biotechnology acquisitions of 2026 and underscores the growing strategic importance of immunology assets within the pharmaceutical industry.

Under the terms of the agreement, AbbVie (NYSE: ABBV) will acquire Apogee Therapeutics (NASDAQ: APGE) for $135.11 per share in cash, representing a substantial premium to the company's previous closing price. The transaction has been unanimously approved by the boards of directors of both companies and is expected to close during the third quarter of 2026, pending regulatory approvals and shareholder consent.

The acquisition significantly strengthens AbbVie’s (NYSE: ABBV) already dominant position in immunology, a therapeutic area that has long been a key growth driver for the company. Investors have closely watched AbbVie’s efforts to diversify and expand beyond its established blockbuster therapies, and Apogee’s pipeline provides a meaningful opportunity to accelerate that strategy.

Apogee Therapeutics (NASDAQ: APGE) brings a portfolio of clinical-stage candidates targeting inflammatory, immunological, and respiratory diseases. Among the most attractive assets are its programs focused on atopic dermatitis (AD) and asthma, two large and rapidly evolving markets where demand for more effective biologic therapies continues to grow. These assets complement AbbVie’s existing expertise and could strengthen its long-term competitive position against major rivals in the immunology space.

The market’s reaction reflects both the size of the acquisition premium and the validation of Apogee’s scientific platform. For biotechnology investors, a large-cap pharmaceutical company committing nearly $11 billion to acquire a clinical-stage developer serves as a strong endorsement of the underlying pipeline and future commercial potential.

For AbbVie (NYSE: ABBV), the transaction represents a strategic bet on long-term growth rather than near-term earnings accretion. While investors will likely focus on integration and development risks, the deal enhances the company’s pipeline depth at a time when large pharmaceutical firms are increasingly competing for high-quality immunology assets.

The sharp rally in Apogee Therapeutics (NASDAQ: APGE) shares reflects the certainty provided by the all-cash offer, while AbbVie’s move highlights the continued consolidation trend across the biotechnology sector as major drugmakers seek innovative growth platforms and next-generation therapies.